CN107698575A - The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application - Google Patents

The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application Download PDF

Info

Publication number
CN107698575A
CN107698575A CN201710893416.4A CN201710893416A CN107698575A CN 107698575 A CN107698575 A CN 107698575A CN 201710893416 A CN201710893416 A CN 201710893416A CN 107698575 A CN107698575 A CN 107698575A
Authority
CN
China
Prior art keywords
bases
compound
methyl
oxos
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710893416.4A
Other languages
Chinese (zh)
Inventor
张惠斌
王丽蕊
武振威
高颖生
李向阳
杨飞
杨一飞
张剑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201710893416.4A priority Critical patent/CN107698575A/en
Publication of CN107698575A publication Critical patent/CN107698575A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to new difunctional small molecule and its pharmaceutically acceptable salt, the hydrate or preparation method of prodrug and these compounds and its Pharmaceutical composition in treatment tumour, inflammation, the application in disease such as is immunized.Difunctional small molecule of the present invention is a kind of protein degradation targeting association (PROTACs), and they being capable of selective induction BET protein degradations.Difunctional small molecule is obtained by the present invention in that being connected BET protein micromolecular inhibitors with cereblon protein ligands in E3 SCF-complexes with linking arm.

Description

The bifunctional molecule and its system of novel B ET protein degradations ligand-mediated cereblon Standby and application
Technical field
The present invention relates to the preparation method of new difunctional small molecule and its pharmaceutically acceptable salt, hydrate or prodrug And these compounds and its Pharmaceutical composition be in treatment tumour, inflammation, the application in disease such as it is immunized.It is of the present invention double Function small molecule is a kind of protein degradation targeting association (PROTACs), and they being capable of selective induction BET protein degradations.This Invention is by using linking arm by cereblon protein ligands in BET protein micromolecular inhibitors and E3 SCF-complexes Connection obtains difunctional small molecule.
Background technology
The ubiquitination of target protein generally requires the collective effect of three enzymes, is E1 activating enzymes first to activate ubiquitin molecule, Then E2 desmoenzymes carry out the ubiquitin molecule of " clasping " activation, finally will be general by the E3 ubiquitin ligases and E2 of binding specificity substrate Fibroin is covalently transferred on one or more lysine residues of target protein.This mechanism of degradation to specific protein high special What system was mainly determined by E3 ubiquitin ligases, therefore E3 ligases are conclusive central angle in the degradation process of target protein Color.E3 ubiquitin ligases containing Ring domains are a huge E3 ubiquitin ligase monoids, are responsible for probably about 20% Proteins ubiquitinization is degraded, and the degraded event that the Cullin-Ring Ligase (CRL) being made up of Cullin albumen etc. are regulated and controled, Occupy sizable ratio wherein.The E3 complexs that DDB1, CUL4 and ROC1 are formed are that an attested ubiquitination connects Enzyme is connect, DNA reparation, duplication and transcription can be adjusted.Research finds that other many factors also assist in E3 proteasome complex Formation, these factors are the CUL4 correlation factors of DDB1 mono- by Uniform Name, i.e. DCAF.Although CRBN is presently believed to be participation The correlation factor that E3 compounds are formed, but its major function in the complex is unclear.Cereblon ubiquitination target eggs Cause FGF8 (FGF8) and Fibroblast growth factor-10 (FGF10) to increase in vain, illustrate ubiquitination enzyme Complex grows particularly significant for fetal mouse limb.
Lenalidomide is used to treat immunological diseases and tumour, including Huppert's disease.Research shows that lenalidomide can be with With reference to cereblon, so as to trigger transcription factor Ikaros (IKZF1) and Aiolos (IKZF3) ubiquitination and degraded, these Growth of the transcription factor for Huppert's disease is of crucial importance.In the treatment of current Huppert's disease, height expression The effect of cereblon is with lenalidomide or similar medicine is closely related.
BET protein families are considered as the potential target spot of numerous diseases especially cancer, obtain many research institutes and medicine enterprise Concern.BET family proteins include four member proteins BRD2, BRD3, BRD4 and BRDT, and each albumen includes two independences Bromodomain (BD1, BD2.Wherein, BRD2, BRD3 and BRD4 are widely distributed, can almost be sent out in all cells of human body It is existing, and BRDT is only distributed in testis.Bromodomain domains are one highly conserved by about 110 Amino acid profiles Protein function domain, albumen are made up of four α spirals (Z, A, B, C) and two Loop (ZA, BC), can form hydrophobic region Domain, identify and combine the lysine residue of acetylation.
BRD4 plays a significant role in regulatory gene transcription, many studies have shown that BRD4 is raised and arrived target gene Super enhancer region, promote the transcription of the oncogene such as c-MYC, Bcl-X1 and BCL-6.Because BRD4 is in regulation oncogene turn Key effect in record, potential anti-tumor target is become, combined using BET inhibitor interference BRD4 with target gene, under The oncogene such as c-MYC are adjusted, reach antitumor purpose.
In recent years, BET protein inhibitors are by domestic and international researcher's extensive concern, and lot of documents and patent are to BET eggs White inhibitor is reported.Up to now, domestic and international pharmacy corporation, colleges and universities and research institution apply for that more than 200 pieces are related to BET altogether The patent of protein inhibitor.Although successfully being listed still without BET inhibitor, share 16 drug candidates and be in the I/II phases and face Bed conceptual phase, principal indication is malignant tumour.Although BET inhibitor is shown in numerous experiment in vitro and animal model Good active anticancer and tolerance, but clinical research still finds there are problems that.
The difunctional small molecule designed in the present invention can carry out ubiquitination mark to BRD4 albumen, and inducible protein is degraded, Antitumous effect is better than BET inhibitor.Suppress BRD4 albumen to generally require to maintain medicine into higher concentration for a long time, it is possible to Cause serious side effect;And inducible protein degraded only needs a small amount of medicine can, this process is similar to catalytic reaction, And the medicine of equimolar amounts is not needed, so medicine dosage can be reduced using difunctional small molecule, mitigate toxic side effect.
The content of the invention
It is an object of the invention to provide some new difunctional small molecules and its pharmaceutically acceptable salt, hydrate or Prodrug.These compounds have the function of induction BET protein degradations, available for preparing new type antineoplastic medicine.The tumour can be But it is not limited to the white blood of Huppert's disease, stomach cancer, lung cancer, breast cancer, the cancer of the esophagus, colon cancer, medulloblastoma, acute myelogenous Disease, chronic leukemia, prostate cancer, hepatoma, renal cell carcinoma, cervical carcinoma, cutaneum carcinoma, oophoroma, colon cancer, neuroglia Knurl, thyroid cancer or cancer of pancreas.
The present invention also aims to provide a kind of preparation method for synthesizing new difunctional small molecule.
Another object of the present invention is to provide a kind of pharmaceutical preparation containing new difunctional small molecule.
Detailed description content is as follows:
To achieve these goals, the invention provides the difunctional small molecule shown in below formula or its can pharmaceutically connect Salt, hydrate or the prodrug received:
A-L-B
Wherein:
A is the smaller ligand of cereblon albumen in E3 SCF-complexes, comprising amides compound, adjacent benzene Diimide compounds, Thalidomide or derivatives thereof, lenalidomide or derivatives thereof, pomalidomide or derivatives thereof, portion Dispensing body general structure is as follows:
Wherein:
W is selected from CH2, C=O, SO2, NH, N- alkyl;
X is selected from O, S;
Y is selected from NH, N- alkyl, N- aryl, N- heterocycles, N- cycloalkyl, O, S;
Z be selected from-alkyl ,-cycloalkyl ,-Cl ,-F;
G, G ' is selected from-H ,-alkyl ,-OH ,-CH2- heterocycle;
Q1、Q2、Q3、Q4Selected from C, N, NO.
L is linking arm, comprising non-linear chain, aliphatic chain, fragrant chain, Heteroaryl ring structures chain, passes through covalent bond and A and B It is connected, part is connected shown in arm configuration below formula:
Wherein:
N is selected from the integer between 1-10.
B is BET protein inhibitors or derivatives thereof.
Present invention is preferably related to the difunctional small molecule shown in below formula (Ia), (IIa) and (IIIa) or its pharmaceutically Acceptable salt, hydrate or prodrug:
Wherein:
R1Selected from-H ,-D ,-CH3、-CH2F、CHF2、-CF3、-CH2D、-CHD2、-CD3、-CH2CH3、-CH2CH2CH3
R2、R3It is identical or different, separately selected from-H ,-D ,-F ,-Cl ,-Br ,-I ,-NO2、-CN、-NH2、-OH、- CH3、-CH2F、CHF2、-CF3、-CH2D、-CHD2、-CD3、-CH2CH3
N is selected from the integer between 1-10.
The present invention, which is more preferably related to difunctional small molecule shown in formula (Ia), (IIa) and (IHa) or its, can pharmaceutically connect Salt, hydrate or the prodrug received:
Wherein:
R1Selected from-H ,-CH3、-CH2CH3
R2、R3It is identical or different, separately selected from-H ,-F ,-Cl ,-Br ,-CH3、-CH2F、CHF2、-CF3、- CH2D、-CHD2、-CD3
N is selected from the integer between 1-6.
Preferred compounds of the invention includes, but are not limited to:
Ia class compounds:
2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro quinoline azoles Quinoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- Oxoisoindolines -4- bases) acetamide;
2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro Quinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxy piperazines Pyridine -3- bases) -1- oxoisoindolines -4- bases) acetamide;
2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-dihydro quinoline Oxazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxies For piperidines -3- bases) -1- oxoisoindolines -4- bases) acetamide;
2- (2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxo -4- phenyl-two Hydrogen quinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) acetamide;
IIa class compounds:
3- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide;
4- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) butyramide;
5- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) pentanamide;
6- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caproamide;
7- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) heptamide;
8- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caprylamide;
IIIa class compounds
3- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide;
5- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) pentanamide;
6- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caproamide;
7- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) heptamide;
The structure of part of compounds is:
Ia class compounds:
IIa class compounds:
IIIa class compounds
Compound shown in formula (Ia), (IIa) and (IIIa) can contain asymmetric or chiral centre, therefore can be with Different stereoisomeric forms in any ratio are present.All stereoisomeric forms in any ratio of the compounds of this invention, including but not limited to diastereoisomer, Enantiomter and atropisomer and their mixture (such as racemate), are included within the scope of the present invention.
Compound shown in formula (Ia), (IIa) and (IIIa) can also exist with different tautomeric forms, it is all this A little forms are included in the scope of the invention.Belong to " dynamic isomer " or " tautomeric form " to refer to build mutually via low energy The constitutional isomer of the different-energy of conversion.
According to the present invention, pharmaceutically acceptable salt includes the addition salts formed with following acid:Hydrochloric acid, hydrobromic acid, sulfuric acid, Phosphoric acid, methanesulfonic acid, ethyl sulfonic acid, p-methyl benzenesulfonic acid, benzene sulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, Citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid etc..Hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, tartaric acid, phosphoric acid, lactic acid, Pyruvic acid, acetic acid, trifluoroacetic acid, maleic acid, benzene sulfonic acid, butanedioic acid and similar known acceptable acid are into salt.
In addition, present invention additionally comprises the prodrug of derivative of the present invention.The prodrug of derivative of the present invention be formula (Ia), (IIa) and (IIIa) derivative, their own may have weaker activity even without activity, but upon administration, (such as by metabolism, solvolysis or other mode) is converted to corresponding biologically active form under physiological condition.
The present invention can contain the difunctional small molecule of above formula (Ia), (IIa) and (IIIa) and its pharmaceutically acceptable Salt, hydrate are prepared by mixing into composition, and be prepared into and clinically may be used as active ingredient with pharmaceutically acceptable excipient The formulation of receiving, above-mentioned excipient refer to diluent, adjuvant or the carrier available for pharmaceutical field.Above-mentioned formulation refers to clinic Upper conventional injection, tablet, capsule etc..
Compound of the present invention or its pharmaceutically acceptable salt, hydrate, prodrug can be used as unique antitumor Medicine is used alone, or can be used in combination with the antineoplastic listed, for Prevention tumour etc..
Examples provided hereinafter and preparation example further elucidate and illustrated the compounds of this invention and its preparation side Method.It should be appreciated that the scope that the scope of following examples and preparation example is not limit the invention in any way.
The compounds process for production thereof of formula (Ia), method are as follows:
Step a:Compound I reacts to obtain compound II with paratoluensulfonyl chloride;
Step b:Compound II reacts to obtain compound III with Sodium azide;
Step c:Compound III reacts to obtain compound IV with bromo-acetic acid tert-butyl;
Step d:Compound IV reacts to obtain compound V with trifluoroacetic acid;
Step e:Compound V reacts to obtain compound VI with thionyl chloride;
Step f:Compound VI and lenalidomide or derivatives thereof reaction obtain compound VII;
Step g:Compound VIII and VII reacts to obtain the compound of formula (Ia) expression;
The compounds process for production thereof of formula (IIa), method are as follows:
Step h:Compound IX and lenalidomide or derivatives thereof reaction obtain compound X;
Step i:Compound X reacts to obtain compound XI with trifluoroacetic acid;
Step j:Compound XII and XI reacts to obtain the compound of formula (IIa) expression;
The compounds process for production thereof of formula (IIIa), method are as follows:
Step k:Compound XIH and XVI reacts to obtain compound XV;
Step l:Compound XV and lenalidomide or derivatives thereof reaction obtain the compound of formula (IIIa) expression;
Wherein, R1、R2、R3It is as defined above with n.
Embodiment
It is not required to be further described, it is believed that those skilled in the art, can be at utmost by description above Using the present invention.Therefore, examples provided below is only that the present invention is furture elucidated, is not meant to any Mode limits the scope of the invention.
Raw material can obtain from commercial channels, or be prepared by methods known in the art, or according to side described herein It is prepared by method.
The structure of compound by nuclear magnetic resonance (1H-NMR) and/or mass spectrum (MS) determines.NMR measure is to use ACF- 300BRUK type NMRs, measure solvent is deuterochloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-D6), TMS are interior Mark.MS measure HP1100 type mass spectrographs.Column chromatography uses 200-300 mesh silica gel (Haiyang Chemical Plant, Qingdao's production).
Ia class compound synthesis
Embodiment 1:Preparation 2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxo -4- phenyl - Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl)-N- (2- (2,6- dioxy piperazines Pyridine -3- bases) -1- oxoisoindolines -4- bases) acetamide;(I-1), its structural formula is as follows:
Step 1) 2- hydroxyethyl -4- toluene sulfonic acides esters (1a)
Ethylene glycol (4.00g, 64.05mmol) is dissolved in 5mL pyridines, be added portionwise paratoluensulfonyl chloride (6.14g, 32.22mmol), after being stirred at room temperature 4 hours, 6mol/L hydrochloric acid (40mL) is added, is extracted with ethyl acetate, saturated common salt washing, Collected organic layer, anhydrous sodium sulfate drying, decompression boil off organic solvent, and residue is purified by silica gel column chromatography, use Petrol ether/ethyl acetate (V/V=20/1-10/1) affords colourless liquid, weight 2.34g, yield 33.58%.
1H NMR (300MHz, CDCl3) δ 7.81 (d, J=8.3Hz, 2H), 7.36 (d, J=8.0Hz, 2H), 4.16-4.12 (m, 2H), 3.85-3.78 (m, 2H), 2.45 (s, 3H), 2.01 (d, J=19.0Hz, 1H).
Step 2) 2- hydroxyethyls nitrine (1b)
1a (2g, 9.25mmol) and sodium azide (1.2g, 18.5mmol) are dissolved in 5mL acetone and 5mL water mixed liquids, It is heated to reflux adding 20mL water in 16 hours, is extracted with ethyl acetate, saturated aqueous sodium carbonate is washed, and saturated common salt washing, is collected Organic layer, anhydrous sodium sulfate drying, decompression boil off organic solvent, obtain colourless liquid, weight 0.73g, yield 90.64%.
1H NMR (300MHz, CDCl3) δ 3.82-3.74 (m, 2H), 3.49-3.39 (m, 2H), 2.01 (s, 1H).
Step 3) the 2- nitrine ethoxyacetic acid tert-butyl esters (1c)
1b (0.65g, 7.46mmol) and bromo-acetic acid tert-butyl (1.6g, 8.21mmol) are dissolved in 15mL tetrahydrofurans, Stirred 10 minutes in ice-water bath, sodium hydride (0.53g, 22.39mmol) is added portionwise, it is small to continue the reaction 0.5 in ice-water bath Shi Hou, react at room temperature 3 hours, add 30mL water, be extracted with ethyl acetate, saturated common salt washing, collected organic layer, anhydrous slufuric acid Sodium is dried, and decompression boils off organic solvent, and residue is purified by silica gel column chromatography, uses petrol ether/ethyl acetate (V/V =30/1-20/1) afford colourless liquid, weight 0.43g, yield 28.63%.
1H NMR (300MHz, CDCl3) δ 4.06-4.00 (m, 2H), 3.76-3.70 (m, 2H), 3.48-3.41 (m, 2H), 1.49 (d, J=5.8Hz, 9H).
Step 4) 2- nitrine ethoxyacetic acid (1d)
1c (0.43g, 2.14mmol) is dissolved in 4mL dichloromethane, adds 1mL trifluoroacetic acids, is reacted at room temperature 3 hours Afterwards, decompression boils off organic solvent, obtains brown liquid, weight 0.29g.
Step 5) 2- nitrine Ethoxyacetyl chloride (1e)
1d (0.29g, 2.03mmol) is dissolved in 4mL dichloromethane, 1mL thionyl chlorides is added, adds 2 drop DMF and urge Change, after being heated to reflux 4 hours, decompression boils off organic solvent, obtains brown liquid, weight 0.33g.
Step 6) 2- (2- nitrine ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- Base) acetamide (1f)
Lenalidomide (0.26g, 0.95mmol) is dissolved in 3mL 1-METHYLPYRROLIDONEs, addition 1e (0.32g, 1.9mmol), after reacting at room temperature 4 hours, 20mL water is added, there is solid precipitation, filtered, dry crude product, pass through silica gel column chromatography Chromatographic purifying, yellow solid, weight 0.21g, yield are afforded using methylene chloride/methanol (V/V=150/1-100/1) 55.13%.
Step 7) 2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-two Hydrogen quinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- Base) -1- oxoisoindolines -4- bases) acetamide (I-1)
By 6- (3,5- dimethyl isoxazole -4- bases) -1- methyl 4-phenyls -3- (propyl- 2- alkynes -1- bases) -3,4- dihydro quinolines Oxazoline -2 (1H) -one (0.06g, 0.161mmol), 1f (0.064g, 0.161mmol) and Salzburg vitriol (0.008g, 0.032mmol) it is dissolved in 2mL dichloromethane, in 2mL methanol and 2mL water mixed liquids, is stirred at room temperature 10 minutes, adds ascorbic acid Sodium (0.013g, 0.065mmol), after reacting at room temperature 4 hours, 20mL water is added, is extracted with dichloromethane, saturated common salt washing, Collected organic layer, anhydrous sodium sulfate drying, decompression boil off organic solvent, and residue is purified by silica gel column chromatography, use Methylene chloride/methanol (V/V=100/1-30/1) affords yellow solid, weight 0.057g, yield 45.72%.
MS (ESI, m/z):757.30[M-H]-
1H NMR (300MHz, CDCl3) δ 8.81 (d, J=34.0Hz, 1H), 8.40 (s, 1H), 8.17 (s, 1H), 7.69 (d, J=7.5Hz, 1H), 7.50 (d, J=7.1Hz, 1H), 7.31 (s, 2H), 7.24 (d, J=4.9Hz, 3H), 7.10 (d, J= 8.0Hz, 1H), 6.93 (d, J=7.9Hz, 2H), 5.70 (s, 1H), 5.30-5.16 (m, 1H), 5.02 (s, 1H), 4.41 (d, J =70.1Hz, 5H), 3.98 (s, 2H), 3.43 (s, 3H), 2.82 (s, 3H), 2.39-2.02 (m, 7H), 1.78 (s, 3H).
Embodiment 2:Prepare 2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxo -4- benzene Base-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl)-N- (2- (2, 6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) acetamide (I-2), its structural formula is as follows:
Synthesis step is the same as embodiment 1
MS (ESI, m/z):800.00[M-H]-
1H NMR (300MHz, CDCl3) δ 9.18 (d, J=78.9Hz, 1H), 8.63 (d, J=14.2Hz, 1H), 7.81 (dd, J=13.0,7.8Hz, 2H), 7.69 (d, J=7.5Hz, 1H), 7.45 (dd, J=13.2,7.5Hz, 1H), 7.30 (dd, J =13.1,5.4Hz, 5H), 7.06 (d, J=8.5Hz, 1H), 6.88 (dd, J=8.2,4.1Hz, 2H), 5.75 (d, J= 10.6Hz, 1H), 5.22 (d, J=9.3Hz, 1H), 5.13-4.99 (m, 1H), 4.51-4.30 (m, 4H), 4.07 (dt, J= 15.2,8.7Hz, 3H), 3.87 (s, 2H), 3.76-3.56 (m, 4H), 3.38 (d, J=2.0Hz, 3H), 2.82 (dd, J= 11.9,4.6Hz, 2H), 2.30 (t, J=17.4Hz, 4H), 2.15 (t, J=12.0Hz, 4H), 1.96 (s, 1H).
Embodiment 3:Preparation 2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos - 4- phenyl-dihydroquinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethyoxyl) - N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) acetamide (I-3), its structural formula are as follows:
Synthesis step is the same as embodiment 1
MS (ESI, m/z):844.05[M-H]-
1H NMR (300MHz, CDCl3) δ 9.17 (d, J=49.8Hz, 2H), 7.75 (d, J=7.0Hz, 1H), 7.63 (s, 1H), 7.39 (dd, J=55.8,14.0Hz, 6H), 7.08 (d, J=7.9Hz, 1H), 6.90 (s, 2H), 5.82 (s, 1H), 5.23 (s, 1H), 4.51-4.12 (m, 6H), 3.60 (dd, J=62.3,41.9Hz, 14H), 2.87 (s, 2H), 2.25 (t, J= 34.5Hz, 9H), 1.81 (s, 2H).
Embodiment 4:Prepare 2- (2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxygen Generation -4- phenyl-dihydroquinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethoxy Base) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) acetamide (I-4), its structure Formula is as follows:
Synthesis step is the same as embodiment 1
MS (ESI, m/z):888.05[M-H]-
1H NMR (300MHz, CDCl3) δ 9.36 (d, J=24.8Hz, 1H), 9.17 (s, 1H), 7.88-7.62 (m, 3H), 7.48 (d, J=7.6Hz, 1H), 7.34 (s, 4H), 7.07 (d, J=8.1Hz, 1H), 6.89 (d, J=12.3Hz, 2H), 5.79 (s, 1H), 5.17 (d, J=14.4Hz, 2H), 4.45 (s, 4H), 4.13 (s, 2H), 4.05 (d, J=16.7Hz, 1H), 3.95- 3.02 (m, 18H), 2.87 (s, 2H), 2.57-2.02 (m, 9H), 1.97 (s, 1H)
IIa class compound synthesis
Embodiment 5:Prepare 3- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitraes - Dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) Propionamide (II-1), its structural formula are as follows:
Step 1) the tert-butyl group (3- ((2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) amino) -3- Propionyl) carbamate (2a)
Lenalidomide (0.2g, 0.77mmol), 3- ((tertbutyloxycarbonyl) amino) propionic acid (0.16g, 0.85mmol) is molten In 2mL acetonitriles, pyridine (0.18g, 2.31mmol) is added, the POCl3 of 2ml dilution in acetonitrile is added under condition of ice bath (0.14g, 0.92mmol), it is added dropwise and removes ice bath, after reacting at room temperature 4 hours, adds 20mL water, be extracted with ethyl acetate, Saturated common salt is washed, collected organic layer, anhydrous sodium sulfate drying, and decompression boils off organic solvent, and residue passes through silica gel column chromatography Chromatographic purifying, faint yellow solid, weight 0.16g, yield are afforded using methylene chloride/methanol (V/V=100/1-40/1) 48.18%.
Step 2) 3- amino-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide (2b)
2a (0.16g, 0.37mmol) is dissolved in 4mL dichloromethane, adds 1mL trifluoroacetic acids, is reacted at room temperature 3 hours Afterwards, decompression boils off organic solvent, obtains yellow solid, weight 0.13g.
Step 3) 3- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro quinolines Oxazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide (II-1)
By 2b (0.12g, 0.36mmol) and 2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxo -4- benzene Base-Isosorbide-5-Nitrae-dihydroquinazoline 3 (2H)-yl) acetic acid (0.12g, 0.30mmol) is dissolved in 2mlDMF, add N- ethyl diisopropylamines (0.12g, 0.91mmol) adds 2- (7- aoxidizes BTA)-N, N, N ', N '-tetramethylurea hexafluoro phosphorus after reacting 10 minutes Acid esters (0.14g, 0.36mmol), after reacting at room temperature 4 hours, 20mL water is added, is extracted with dichloromethane, saturated common salt washing, Collected organic layer, anhydrous sodium sulfate drying, decompression boil off organic solvent, and residue is purified by silica gel column chromatography, use Methylene chloride/methanol (V/V=100/1-30/1) affords yellow solid, weight 0.152g, yield 71.35%.
MS (ESI, m/z):702.00[M-H]-
1H NMR (300MHz, DMSO) δ 11.02 (s, 1H), 9.85 (s, 1H), 8.11 (s, 1H), 7.80 (d, J= 7.0Hz, 1H), 7.53-7.43 (m, 2H), 7.36-7.23 (m, 6H), 7.18 (d, J=11.0Hz, 1H), 7.07 (d, J= 8.5Hz, 1H), 5.65 (d, J=3.4Hz, 1H), 5.14 (d, J=8.4Hz, 1H), 4.38 (d, J=8.4Hz, 2H), 3.33 (s, 8H), 3.17 (s, 2H), 2.54 (s, 3H), 2.31 (d, J=2.8Hz, 3H), 2.14 (d, J=1.9Hz, 3H).
Embodiment 6:Prepare 4- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitraes - Dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) Butyramide (II-2);Its structural formula is as follows:
Synthesis step is the same as embodiment 5
MS (ESI, m/z):716.05[M-H]-
1H NMR (300MHz, DMSO) δ 11.03 (s, 1H), 9.82 (s, 1H), 8.03 (s, 1H), 7.81 (d, J= 6.8Hz, 1H), 7.50 (d, J=7.4Hz, 2H), 7.36 (s, 4H), 7.29 (d, J=8.1Hz, 3H), 7.10 (d, J=8.5Hz, 1H), 5.69 (s, 1H), 5.15 (dd, J=13.3,4.8Hz, 1H), 4.38 (d, J=5.6Hz, 2H), 3.35 (s, 7H), 3.16 (s, 2H), 2.58 (d, J=29.7Hz, 3H), 2.44-2.29 (m, 6H), 2.17 (d, J=1.4Hz, 3H).
Embodiment 7:Prepare 5- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitraes - Dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) Pentanamide (II-3);Its structural formula is as follows:
Synthesis step is the same as embodiment 5
MS (ESI, m/z):730.05[M-H]-
1H NMR (300MHz, DMSO) δ 11.01 (s, 1H), 9.77 (s, 1H), 7.96 (s, 1H), 7.80 (d, J= 7.5Hz, 1H), 7.47 (d, J=8.2Hz, 2H), 7.34 (d, J=4.3Hz, 4H), 7.26 (d, J=7.2Hz, 3H), 7.07 (d, J=9.0Hz, 1H), 5.66 (s, 1H), 5.18-5.08 (m, 1H), 4.40 (dd, J=26.9,9.8Hz, 4H), 3.30 (s, 3H), 2.36 (s, 2H), 2.30 (s, 3H), 2.14 (s, 3H), 1.98 (s, 2H), 1.51 (d, J=47.6Hz, 6H), 1.23 (s, 2H).
Embodiment 8:Prepare 6- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitraes - Dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) Caproamide (II-4);Its structural formula is as follows:
Synthesis step is the same as embodiment 5
MS (ESI, m/z):744.15[M-H]-
1H NMR (300MHz, CDCl3) δ 8.91 (d, J=17.4Hz, 1H), 8.42 (s, 1H), 7.76-7.46 (m, 3H), 7.29 (d, J=32.1Hz, 5H), 7.08 (d, J=8.8Hz, 1H), 6.90 (d, J=8.3Hz, 1H), 6.80 (s, 1H), 6.48 (s, 1H), 5.58 (s, 1H), 5.01 (s, 1H), 4.30 (s, 2H), 3.03 (s, 2H), 2.67 (s, 3H), 2.27 (s, 2H), 2.08 (s, 3H), 1.65 (s, 8H), 1.26 (d, J=39.9Hz, 7H).
Embodiment 9:Prepare 7- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitraes - Dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) Heptamide (II-5);Its structural formula is as follows:
MS (ESI, m/z):758.10[M-H]-
1H NMR (300MHz, DMSO) δ 11.00 (s, 1H), 9.75 (s, 1H), 7.82 (dd, J=15.5,10.5Hz, 2H), 7.49 (t, J=6.7Hz, 2H), 7.35 (d, J=4.0Hz, 4H), 7.27 (d, J=9.1Hz, 3H), 7.08 (d, J= 8.2Hz, 1H), 5.66 (s, 1H), 5.14 (dd, J=13.1,5.1Hz, 1H), 4.36 (d, J=4.1Hz, 2H), 3.31 (s, 5H), 3.05 (d, J=6.3Hz, 2H), 2.36 (d, J=7.3Hz, 2H), 2.32 (s, 3H), 2.15 (s, 3H), 2.01 (s, 2H), 1.60 (s, 2H), 1.33 (dd, J=33.6,12.8Hz, 8H).
Embodiment 10:Preparation 8- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxo -4- phenyl -1, 4- dihydroquinazolines -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- Base) caprylamide (II-6);Its structural formula is as follows:
MS (ESI, m/z):772.05[M-H]-
1H NMR (300MHz, DMSO) δ 11.00 (s, 1H), 9.74 (s, 1H), 7.87 (s, 1H), 7.82 (d, J= 6.8Hz, 1H), 7.49 (d, J=7.1Hz, 2H), 7.35 (d, J=3.9Hz, 4H), 7.27 (d, J=10.7Hz, 3H), 7.08 (d, J=8.3Hz, 1H), 5.66 (s, 1H), 5.14 (dd, J=13.1,4.9Hz, 1H), 4.34 (t, J=10.8Hz, 2H), 3.28 (d, J=20.6Hz, 5H), 3.04 (d, J=5.7Hz, 2H), 2.40-2.34 (m, 2H), 2.32 (s, 3H), 2.16 (s, 3H), 2.03 (d, J=9.4Hz, 2H), 1.60 (s, 2H), 1.37 (d, J=6.2Hz, 2H), 1.26 (d, J=12.7Hz, 8H)
Embodiment 11:Prepare 3- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-two Hydrogen quinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide (III- 1);Its structural formula is as follows:
Step 1) 3- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro quinoline azoles Quinoline -3 (2H)-yl) propionic acid (3a)
By 6- (3,5- dimethyl isoxazole -4- bases) -1- methyl 4-phenyls -3,4- dihydroquinazoline -2 (1H) -one (0.2g, 0.60mmol), 3- bromo-propionic acids (0.14g, 0.90mmol), is dissolved in 2mL DMF, and sodium hydrogen is added under condition of ice bath (0.029g, 1.2mmol), half an hour recession removes ice bath, after reacting at room temperature 4 hours, adds 20mL water, is extracted with ethyl acetate, Saturated common salt is washed, collected organic layer, anhydrous sodium sulfate drying, and decompression boils off organic solvent, and residue passes through silica gel column chromatography Chromatographic purifying, faint yellow solid, weight 0.16g, yield 65.78% are afforded using petrol ether/ethyl acetate (V/V=4/1).
Step 2) 3- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro quinoline azoles Quinoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide (III-1)
3a (0.16g, 0.40mmol) and lenalidomide (0.11g, 0.43mmol) are dissolved in 4mL acetonitriles, add pyridine (0.09g, 1.18mmol), it is slowly added dropwise under condition of ice bath and is dripped with the POCl3 (0.07g, 0.47mmol) of 2ml dilution in acetonitrile After room temperature condition reaction being transferred to after adding 3 hours, add a small amount of water decompression to boil off acetonitrile, add 20mL water, use ethyl acetate Extraction, saturated common salt washing, collected organic layer, anhydrous sodium sulfate drying, decompression boil off organic solvent, and residue passes through silicagel column Chromatographic purification, faint yellow solid is afforded using methylene chloride/methanol (V/V=100/1-20/1), weight 0.08g, is received Rate 31.35%.
MS (ESI, m/z):645.25[M-H]-
1H NMR (300MHz, DMSO) δ 10.98 (s, 1H), 9.86 (s, 1H), 7.70 (d, J=7.3Hz, 1H), 7.45 (d, J=6.8Hz, 1H), 7.34 (d, J=4.1Hz, 4H), 7.22 (d, J=10.5Hz, 2H), 7.02 (d, J=8.5Hz, 1H), 6.90 (d, J=7.5Hz, 1H), 6.78 (d, J=7.8Hz, 1H), 5.41 (s, 2H), 3.29 (s, 2H), 2.91 (s, 3H), 2.62 (s, 3H), 2.29 (d, J=4.4Hz, 4H), 2.12 (d, J=4.3Hz, 2H), 1.36-1.27 (m, 1H), 1.22 (s, 3H), 0.84 (s, 1H)
Embodiment 12:Prepare 5- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-two Hydrogen quinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) pentanamide (III- 2);Its structural formula is as follows:
MS (ESI, m/z):673.29[M-H]-
1H NMR (300MHz, DMSO) δ 11.00 (s, 1H), 9.75 (s, 1H), 7.80 (s, 1H), 7.49 (s, 2H), 7.34 (s, 3H), 7.21 (d, J=15.6Hz, 3H), 6.91 (d, J=7.2Hz, 1H), 6.80 (d, J=8.0Hz, 1H), 5.42 (s, 1H), 4.29 (d, J=34.4Hz, 2H), 3.52 (s, 1H), 3.29 (s, 2H), 2.99 (d, J=40.9Hz, 4H), 2.64 (s, 1H), 2.34 (s, 4H), 2.17 (s, 2H), 1.34 (s, 2H), 1.24 (s, 6H), 0.85 (s, 1H)
Embodiment 13:Prepare 6- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-two Hydrogen quinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caproamide (III- 3);Its structural formula is as follows:
MS (ESI, m/z):687.30[M-H]-
1H NMR (300MHz, DMSO) δ 11.01 (s, 1H), 9.74 (t, J=17.6Hz, 1H), 7.87 (d, J= 44.1Hz, 1H), 7.51 (dd, J=27.1,21.2Hz, 3H), 7.23 (ddd, J=24.5,20.6,6.5Hz, 5H), 7.07- 6.65 (m, 2H), 5.41 (s, 1H), 4.48-4.22 (m, 2H), 3.86-3.40 (m, 3H), 3.24 (d, J=21.7Hz, 2H), 3.04-2.79 (m, 2H), 2.60 (d, J=17.9Hz, 1H), 2.34 (s, 3H), 2.17 (s, 2H), 1.94 (d, J=24.4Hz, 1H), 1.39-1.17 (m, 9H), 0.84 (d, J=6.1Hz, 2H)
Embodiment 14:Prepare 7- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-two Hydrogen quinazoline -3 (2H)-yl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) heptamide (III- 4);Its structural formula is as follows:
MS (ESI, m/z):702.31[M-H]-
1H NMR (300MHz, DMSO) δ 11.01 (s, 1H), 9.74 (s, 1H), 7.80 (d, J=6.3Hz, 1H), 7.61- 7.41 (m, 2H), 7.40-7.18 (m, 7H), 7.03 (d, J=8.4Hz, 1H), 5.73 (s, 1H), 4.46-4.24 (m, 2H), 3.28 (s, 3H), 2.88 (dd, J=30.0,10.9Hz, 2H), 2.42-2.25 (m, 6H), 2.18 (s, 3H), 1.52 (d, J= 26.4Hz, 4H), 1.29 (dd, J=30.3,5.6Hz, 9H)
Embodiment 15:The protein level determination of activity of compound
The combination of first bromodomain domain of compound and BRD4 albumen n ends (hereinafter referred to as BRD4 (BD1)) is lived Property test using AlphaScreen detection techniques.Compound primary dcreening operation concentration is 500nM.
HEPES buffer solution (50mM HEPES, 100mM NaCl, 0.1%BSA, 0.05%CHAPS, pH7.5) is prepared to be used for Prepare BRD4 (BD1) albumen, Biotin mark histone H 4, testing compound (DMSO 0.1%), donor beads and Acceptor beads solution.Take one piece of 384 orifice plate, according to arrangement, divide on plate testing compound hole, blank control wells (min, Max), positive drug control wells.The μ L of compound solution 5 of various concentrations are separately added into testing compound hole and positive drug hole, it is empty It is white to add the μ L (DMSO 0.1%) of buffer solution 5.Continue to add BRD4 (BD1) albumen to each hole in addition to blank control wells (min) The μ L of solution 5, the μ L of buffer solution 5 are added to blank control wells (min).After being incubated 15 minutes at room temperature, Biotin marks are added per hole The μ L of histone H 4 solution 5, continue at room temperature be incubated 1 hour after, add donor beads and acceptor beads solution 15 μ L, lucifuge are read glimmering with the Alpha mode (λ ex=680, λ em=570) of EnSpire detectors after being incubated at room temperature 1 hour Light numerical value.
Numerical value processing:Inhibiting rate=(Max-Signal)/(Max-Min) × 100%
Wherein:Max:The value that the histone H 4 of Biotin marks is completely combined with albumen
Min:The histone H 4 background values of Biotin marks
Signal:Value under compound respective concentration
S curve is done with compound concentration and corresponding inhibiting rate.Obtain the IC of respective compound50
The experimental result of part of compounds is shown in Table 1:
Inhibitory activity result of the preferred compound of table 1 to BRD4 (BD1).
Compound Inhibiting rate (%) 500nM IC50(nM)
I-1 99.3 14
I-2 100 15
I-3 100 22
I-4 100 22
II-1 94.2 132
II-2 89.3 148
II-3 91.4 133
II-4 98.3 99
II-5 99.2 80
II-6 100 68
III-1 86.3 162
III-2 90.7 143
III-3 95.3 112
III-4 99.6 72
Embodiment 16:Compound cellular level determination of activity
The Activity determination of Compound cellular level uses Celltiter-Glo fluorecyte viability examination methods.Will be in pair Non-small cell lung cancer (NSCLC) A549, H1975 cell, colon cancer HT29, HCT15, HCT116 cell, the mammary gland in number growth period Cancer MDA-MB-231, MDA-MB-468 cell and esophageal squamous cell carcinoma CaES-17 cells are seeded to 96 well culture plates, overnight incubation Afterwards, 37 DEG C of testing compound, 5%CO are added272h is incubated, after terminating, balances measure reagent at room temperature within 30 minutes before detection. 30uL Celltiter-Glo reagents are added per hole, rock 96 orifice plate, 10 minutes inducing cell lysis.By 96 orifice plates at room temperature 2 minutes are incubated to stablize fluorescence signal.Fluorescence values are read using Envision detectors.
Numerical value processing:Inhibiting rate=(Max signal-Compound signal)/(Max signal-Min signal) × 100%
Wherein:Max signal:The maximum read in DMSO effects
Min signal:The only minimum value of medium effect
Compound signal:Value under compound respective concentration
S curve is done with compound concentration and corresponding inhibiting rate.Obtain the IC of respective compound50
The experimental result of part of compounds is shown in Table 2:
The preferred compound of table 2 to non-small cell lung cancer (NSCLC) A549, H1975 cell line, colon cancer HT29, HCT15, The anti-increasing of HCT116 cell lines, breast cancer MDA-MB-231, MDA-MB-468 cell line and esophageal squamous cell carcinoma CaES-17 cell lines Grow active (20uM, 72h).
Embodiment 17:Tablet
With containing compound in claim 1 (by taking the compound of embodiment 1 as an example) 10g, according to the general pressed disc method of pharmacy After adding auxiliary material 20g to mix, 100 are pressed into, every weight 300mg.
Embodiment 18:Capsule
With containing compound in claim 1 (by taking the compound of embodiment 1 as an example) 10g, according to pharmacy capsule will Ask after auxiliary material 20g is mixed, load Capsules, each capsule weight 300mg.
Embodiment 19:Injection
With containing compound in claim 1 (by taking the compound of embodiment 1 as an example) 10g, according to pharmacy conventional method, enter Row charcoal absorption, after 0.65 μm of filtering with microporous membrane, insert nitrogen pot and hydro-acupuncture preparation is made, every fills 2mL, filling altogether 100 bottles.
Although describing the present invention by particular, modification and equivalent variations are for being proficient in this field It will be apparent from for technical staff, and they are included within the scope of the invention.

Claims (7)

1. difunctional small molecule or its pharmaceutically acceptable salt, hydrate or prodrug shown in below formula:
A-L-B
Wherein:
A is the smaller ligand of cereblon albumen in E3 SCF-complexes, includes amides compound, phthalyl Imine compound, Thalidomide or derivatives thereof, lenalidomide or derivatives thereof, pomalidomide or derivatives thereof, partly matches somebody with somebody Body general structure is as follows:
Wherein:
W is selected from CH2, C=O, SO2, NH, N- alkyl;
X is selected from O, S;
Y is selected from NH, N- alkyl, N- aryl, N- heterocycles, N- cycloalkyl, O, S;
Z be selected from-alkyl ,-cycloalkyl ,-Cl ,-F;
G, G ' is selected from-H ,-alkyl ,-OH ,-CH2- heterocycle;
Q1、Q2、Q3、Q4Selected from C, N, NO.
L is linking arm, comprising non-linear chain, aliphatic chain, fragrant chain, Heteroaryl ring structures chain, is connected by covalent bond with A and B, Shown in part connection arm configuration below formula:
Wherein:
N is selected from the integer between 1-10.
B is BET protein inhibitors or derivatives thereof.
2. according to the compound below formula (Ia), (IIa) and (IIIa) described in claim 1,
Wherein:
R1Selected from-H ,-D ,-CH3、-CH2F、CHF2、-CF3、-CH2D、-CHD2、-CD3、-CH2CH3、-CH2CH2CH3
R2、R3It is identical or different, separately selected from-H ,-D ,-F ,-Cl ,-Br ,-I ,-NO2、-CN、-NH2、-OH、-CH3、- CH2F、CHF2、-CF3、-CH2D、-CHD2、-CD3、-CH2CH3
N is selected from the integer between 1-10.
3. according to the compound described in claim 2, wherein:
R1Selected from-H ,-CH3、-CH2CH3
R2、R3It is identical or different, separately selected from-H ,-F ,-Cl ,-Br ,-CH3、-CH2F、CHF2、-CF3、-CH2D、- CHD2、-CD3
N is selected from the integer between 1-6.
4. according to the compound described in claim 1-3, wherein, the compound is one of following compounds or it is acceptable Salt, hydrate or prodrug,
Ia class compounds:
2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxos Isoindoline -4- bases) acetamide;
2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydro quinoline azoles Quinoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- Base) -1- oxoisoindolines -4- bases) acetamide;
2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-dihydro quinoline azoles Quinoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxos Piperidines -3- bases) -1- oxoisoindolines -4- bases) acetamide;
2- (2- (2- (2- (2- (4- ((6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-dihydro quinoline Oxazoline -3 (2H)-yl) methyl) -1H-1,2,3- triazole -1- bases) ethyoxyl) ethyoxyl) ethyoxyl) ethyoxyl)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) acetamide;
IIa class compounds:
3- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide;
4- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) butyramide;
5- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) pentanamide;
6- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caproamide;
7- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) heptamide;
8- (2- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazoline -3 (2H)-yl) acetylamino)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caprylamide;
IIIa class compounds
3- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazolines -3 (2H) - Base)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) propionamide;
5- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazolines -3 (2H) - Base)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) pentanamide;
6- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazolines -3 (2H) - Base)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) caproamide;
7- (6- (3,5- dimethyl isoxazole -4- bases) -1- methyl -2- oxos -4- phenyl-Isosorbide-5-Nitrae-dihydroquinazolines -3 (2H) - Base)-N- (2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -4- bases) heptamide.
5. the preparation method of the compound any one of claim 1-4, is prepared by following methods:
The compounds process for production thereof of formula (Ia), method are as follows:
Step a:Compound I reacts to obtain compound II with paratoluensulfonyl chloride;
Step b:Compound II reacts to obtain compound III with Sodium azide;
Step c:Compound III reacts to obtain compound IV with bromo-acetic acid tert-butyl;
Step d:Compound IV reacts to obtain compound V with trifluoroacetic acid;
Step e:Compound V reacts to obtain compound VI with thionyl chloride;
Step f:Compound VI and lenalidomide or derivatives thereof reaction obtain compound VII;
Step g:Compound VIII and VII reacts to obtain the compound of formula (Ia) expression;
The compounds process for production thereof of formula (IIa), method are as follows:
Step h:Compound IX and lenalidomide or derivatives thereof reaction obtain compound X;
Step i:Compound X reacts to obtain compound XI with trifluoroacetic acid;
Step j:Compound XII and XI reacts to obtain the compound of formula (IIa) expression;
The compounds process for production thereof of formula (IIIa), method are as follows:
Step k:Compound XIII and XVI reacts to obtain compound XV;
Step l:Compound XV and lenalidomide or derivatives thereof reaction obtain the compound of formula (IIIa) expression;
Wherein, R1、R2、R3It is as defined above with n.
6. a kind of pharmaceutical composition include claim 1-4 any one described in compound and its pharmaceutically acceptable salt or Pharmaceutically acceptable carrier, excipient, diluent, assistant agent, medium, or combinations thereof.
7. the compound of any one and its pharmaceutically acceptable salt or the combination described in claim 6 in claim 1-4 Application of the thing in the medicine for treating or preventing cancer is prepared.
CN201710893416.4A 2017-09-26 2017-09-26 The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application Pending CN107698575A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710893416.4A CN107698575A (en) 2017-09-26 2017-09-26 The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710893416.4A CN107698575A (en) 2017-09-26 2017-09-26 The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application

Publications (1)

Publication Number Publication Date
CN107698575A true CN107698575A (en) 2018-02-16

Family

ID=61175036

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710893416.4A Pending CN107698575A (en) 2017-09-26 2017-09-26 The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application

Country Status (1)

Country Link
CN (1) CN107698575A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110204543A (en) * 2019-06-27 2019-09-06 江苏省中医药研究院 A kind of pyrrolopyridine ketone bifunctional molecule compound based on the induction BET degradation of Cereblon ligand
WO2019201123A1 (en) * 2018-04-20 2019-10-24 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals
CN111646977A (en) * 2020-03-12 2020-09-11 杭州医学院 Compound for target ubiquitination degradation of TGF-beta 1 and preparation method and application thereof
US10844039B2 (en) 2018-11-13 2020-11-24 Biotheryx, Inc. Substituted isoindolinones
CN112125885A (en) * 2019-06-25 2020-12-25 中国药科大学 Benzoindole bifunctional molecular derivative and preparation method and application thereof
CN112608302A (en) * 2020-12-28 2021-04-06 郑州大学第一附属医院 Quinazoline derivative for activating targeted ubiquitination degradation of EGFR protein through low oxygen reduction and application thereof
CN113004251A (en) * 2021-03-05 2021-06-22 郑州大学第一附属医院 Quinazoline derivative containing 2-nitroimidazole and application thereof
CN113214203A (en) * 2020-12-16 2021-08-06 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Small molecule compound based on EZH2 protein degradation and application thereof
US11358952B2 (en) 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
WO2022148459A1 (en) * 2021-01-11 2022-07-14 和径医药科技(上海)有限公司 Class of novel smad3 protein degraders and application thereof
CN114853751A (en) * 2022-05-13 2022-08-05 郑州大学第一附属医院 Phenothiazine derivatives and application thereof
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056772A (en) * 2017-01-23 2017-08-18 中国药科大学 Bifunctional molecule and its preparation and the application of BET degradeds are induced based on cereblon parts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056772A (en) * 2017-01-23 2017-08-18 中国药科大学 Bifunctional molecule and its preparation and the application of BET degradeds are induced based on cereblon parts

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019201123A1 (en) * 2018-04-20 2019-10-24 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals
CN111741769A (en) * 2018-04-20 2020-10-02 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method and medical application thereof
TWI813666B (en) * 2018-04-20 2023-09-01 大陸商四川科倫博泰生物醫藥股份有限公司 A kind of multifunctional compound, its preparation method and its application in medicine
US11358952B2 (en) 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
US11945804B2 (en) 2018-04-23 2024-04-02 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
US10844039B2 (en) 2018-11-13 2020-11-24 Biotheryx, Inc. Substituted isoindolinones
US11352338B2 (en) 2018-11-13 2022-06-07 Biotheryx, Inc. Substituted isoindolinones
CN112125885A (en) * 2019-06-25 2020-12-25 中国药科大学 Benzoindole bifunctional molecular derivative and preparation method and application thereof
CN110204543A (en) * 2019-06-27 2019-09-06 江苏省中医药研究院 A kind of pyrrolopyridine ketone bifunctional molecule compound based on the induction BET degradation of Cereblon ligand
CN111646977A (en) * 2020-03-12 2020-09-11 杭州医学院 Compound for target ubiquitination degradation of TGF-beta 1 and preparation method and application thereof
CN111646977B (en) * 2020-03-12 2021-04-16 杭州医学院 Compound for target ubiquitination degradation of TGF-beta 1 and preparation method and application thereof
CN113214203A (en) * 2020-12-16 2021-08-06 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Small molecule compound based on EZH2 protein degradation and application thereof
CN112608302A (en) * 2020-12-28 2021-04-06 郑州大学第一附属医院 Quinazoline derivative for activating targeted ubiquitination degradation of EGFR protein through low oxygen reduction and application thereof
WO2022148459A1 (en) * 2021-01-11 2022-07-14 和径医药科技(上海)有限公司 Class of novel smad3 protein degraders and application thereof
CN116368131A (en) * 2021-01-11 2023-06-30 和径医药科技(上海)有限公司 Novel Smad3 protein degradation agent and application thereof
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
CN113004251A (en) * 2021-03-05 2021-06-22 郑州大学第一附属医院 Quinazoline derivative containing 2-nitroimidazole and application thereof
CN114853751A (en) * 2022-05-13 2022-08-05 郑州大学第一附属医院 Phenothiazine derivatives and application thereof
CN114853751B (en) * 2022-05-13 2024-01-16 郑州大学第一附属医院 Group of phenothiazine derivatives and application thereof

Similar Documents

Publication Publication Date Title
CN107698575A (en) The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application
Abbass et al. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers
CN107056772A (en) Bifunctional molecule and its preparation and the application of BET degradeds are induced based on cereblon parts
CN107698657A (en) Bifunctional molecule and its preparation and application based on VHL parts and the induction BET degradeds of BET inhibitor
CN105263934B (en) It is used as the ketone derivatives of pyrazoles pyrrolizine 4 and its purposes in treatment disease of BET inhibitor
EP3312180B1 (en) Use of pteridinone derivative serving as egfr inhibitor
Kim et al. Synthesis of 1-/2-substituted-[1, 2, 3] triazolo [4, 5-g] phthalazine-4, 9-diones and evaluation of their cytotoxicity and topoisomerase II inhibition
CN110204543A (en) A kind of pyrrolopyridine ketone bifunctional molecule compound based on the induction BET degradation of Cereblon ligand
CN106573906A (en) Piperidine-dione derivatives
Hou et al. Design, synthesis and biological evaluation of novel 7-amino-[1, 2, 4] triazolo [4, 3-f] pteridinone, and 7-aminotetrazolo [1, 5-f] pteridinone derivative as potent antitumor agents
CN106083849A (en) The quaternary condensed or five-membered ring pyrido phthalazone compounds as PARP inhibitor
CN106749513A (en) Bifunctional molecule and its preparation and application based on the induction BET degradeds of VHL parts
CN103224496B (en) Tricyclic antidepressants PI3K and/or mTOR inhibitors
CN110143961A (en) A kind of pyrrolopyridine ketone bifunctional molecule compound based on the induction BET degradation of VHL ligand
Elmasry et al. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold
CN104837844A (en) Pyrazole substituted imidazopyrzines as casein kinase 1D/E inhibitors
CN117653636B (en) Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound
CN107417695A (en) Berbine derivative, its preparation method, pharmaceutical composition and anticancer usage
CN104892573B (en) Act on 3- vinyl-quinoxaline -2 (1H) -one derivative of FGFR-1 and its preparation method and application
CN107141284B (en) Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage
CN106117182B (en) Quinazoline-N- phenethyl tetrahydroisoquinolicompounds compounds and its preparation method and application
CN107501279A (en) Furoquinoline cyclohexadione compounds and its medical usage
Kim et al. Synthesis of 6-chloroisoquinoline-5, 8-diones and pyrido [3, 4-b] phenazine-5, 12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity
CN109400632B (en) Bis-fluoroquinolone oxadiazole urea derivative containing N-methylenoxacin and preparation method and application thereof
CN104822658B (en) It is used as the fused tricyclic amides compound of a variety of kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180216

WD01 Invention patent application deemed withdrawn after publication